Substituted piperazines as inhibitors of KRAS G12C

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12234244
APP PUB NO 20220242875A1
SERIAL NO

17716707

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, have the following structure:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ARAXES PHARMA LLC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Feng, Jun San Diego, US 210 4080
Li, Liansheng San Diego, US 158 5429
Liu, Yi San Diego, US 838 10296
Liu, Yuan San Diego, US 306 2821
Long, Yun Oliver San Diego, US 27 1147
Ren, Pingda San Diego, US 198 6390
Wu, Tao Carlsbad, US 372 4736

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 25, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 25, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 25, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00